Portola Pharmaceuticals

Portola is discovering and developing novel anti-platelet therapeutics for the treatment of acute and chronic thrombotic indications. Portola’s founders are principally founders of the team that developed the cardiovascular product, Integrilin. The company went public in May 2013.